Lonza Group

Synaffix BV is a clinical-stage biotechnology company based in Oss, the Netherlands, specializing in the development of antibody-drug conjugate (ADC) technology for oncology applications. Founded in 2010, the company has created proprietary platforms, including GlycoConnect and HydraSpace, which enhance the efficacy and tolerability of ADCs. GlycoConnect facilitates site-specific and stable conjugation of anti-cancer molecules by modifying naturally-occurring glycan anchor points on antibodies, while HydraSpace improves payload solubility and reduces aggregation potential. Additionally, Synaffix offers a metal-free click chemistry, applicable across the pharmaceutical, biotech, and academic sectors, which allows for the efficient development of ADCs without prior genetic modifications. The company's patent portfolio ensures protection of its innovations and resulting products through at least 2035.

Indapta Therapeutics is a privately held biotechnology company focused on developing a natural killer (NK) cell therapy platform aimed at treating both blood and solid tumor cancers. The company specializes in a proprietary off-the-shelf, non-engineered, and allogeneic G-NK cell designed to enhance the immune response and significantly improve the effectiveness of antibody therapies. Through its innovative approach, Indapta Therapeutics seeks to provide healthcare providers with advanced treatment options for patients suffering from cancer, leveraging the potent antibody-dependent cellular cytotoxicity (ADCC) activity of its NK cell therapy.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Octane Biotech is a medical technology company with advanced bioreactors, bioprocesses, and biomaterials for regenerative medicine solutions and bioengineering.

Micromacinazione S.A. is an engineering company based in Molinazzo di Monteggio, Switzerland, specializing in jet-mill technologies and micronization services for the pharmaceutical and fine chemical industries. Founded in 1970, the company offers tailored micronization solutions that enhance the performance of active pharmaceutical ingredients (APIs) and highly potent compounds, ensuring safety for personnel and the environment. Its services include research and development in pharmaceutical powder technologies, process development, and the design and manufacturing of equipment such as jet mills, glove boxes, and pneumatic conveyors. Micromacinazione's innovative approaches also focus on improving the solubility of poorly soluble drugs, catering to the evolving needs of the pharmaceutical sector. As of 2017, it operates as a subsidiary of Lonza Group Ltd.

PharmaCell is a leading provider of cell-culturing services, specializing in cellular therapies and regenerative medicine. With GMP-certified manufacturing facilities located in Maastricht and Geleen, the company supports the development and production of commercial cell therapy products for prominent players in the industry. PharmaCell's extensive network enables it to collaborate with research and development companies, facilitating the transition of innovative products from laboratory settings to clinical applications. By focusing on unlocking the potential of cell therapies, PharmaCell aims to enhance healthcare outcomes for patients.

HansaBioMed OU, founded in 2007 and located in Tallinn, Estonia, focuses on research and development in the field of exosome sciences and related technologies. The company specializes in the testing and validation of cancers and neurodegenerative diseases, offering products that include proprietary platforms, kits, reagents, and equipment for exosome research. HansaBioMed is particularly known for its expertise in the purification, enrichment, and characterization of extracellular vesicles (EVs), as well as providing scalable and automated purification solutions from various biological sources. Additionally, the company offers services such as bulk and single EV characterization and biomarker assessment through advanced techniques like mass spectrometry and RNA sequencing. As of May 2017, HansaBioMed operates as a subsidiary of Lonza Group Ltd.

Exosomics focuses on creating innovative tests for cancer screening and liquid biopsy through the analysis of circulating extracellular vesicles. The company specializes in biotechnology equipment that enhances the pre-analytical processes necessary to isolate tumor-derived extracellular vesicles and exosomes from human biofluids. By extracting genomic DNA and RNA from these components, Exosomics aims to provide reliable and cost-effective diagnostic solutions. This approach facilitates improved treatment options for cancer patients by enabling more accurate detection and monitoring of the disease.

Capsugel is a prominent developer and manufacturer of high-quality dosage forms and solutions, headquartered in Morristown, New Jersey. The company specializes in producing a variety of capsules, including inhalation, gelatin, clinical, and polymer capsules. These products are designed to enhance the bioavailability, targeted delivery, and overall efficacy of biopharmaceutical, consumer health, and nutritional products. With a strong focus on innovation and reliability, Capsugel serves healthcare companies globally, providing the scientific and engineering expertise necessary to advance the development of better medicines and nutritionals. The company has established a reputation as a leading provider of empty, two-piece hard capsules and is noted for its commitment to quality and value creation in the healthcare sector.

ConnectedYard Inc., based in Campbell, California, specializes in smart technology for outdoor living, starting with pool and hot tub care through its product, pHin. This innovative solution combines a Bluetooth and Wi-Fi-enabled water monitor with a mobile app that simplifies water management. The app alerts users when water chemistry requires adjustment, providing clear dosing instructions for necessary chemicals. Additionally, it offers convenient access to a network of qualified pool service technicians, facilitating on-demand assistance. As ConnectedYard continues to develop its offerings, it aims to expand its smart solutions to cover various aspects of outdoor living, including irrigation and lighting, enhancing the overall experience of backyard management.

InterHealth Nutraceuticals is a developer and manufacturer of proprietary branded nutraceutical ingredients, focusing on the research, marketing, and distribution of these products globally. The company supplies its high-quality ingredients to manufacturers of dietary supplements, functional foods, beverages, and cosmetic products. Among its notable ingredient brands are Super CitriMax, UC-II, ChromeMate, and L-OptiZinc. With a strong commitment to thorough research and outstanding customer service, InterHealth has built a reputation for quality and innovation in the nutraceutical industry since its inception in 1987. The company continues to seek new value-added ingredients and collaborates with clients to create proprietary blends tailored to specific health supplement needs.

TRL is a fast-growing hepatocyte provider with products supporting in vitro evaluation of metabolism, drug-drug interactions, drug transporter activity, toxicity of drug candidates and other applications. Triangle Research Labs has facilities based in Research Triangle Park, North Carolina (USA). Triangle Research Labs was established in 2012 and has quickly gained a reputation for high-quality products and a unique ability to understand each customer’s specific needs. This combination makes TRL a great asset to Lonza’s mission of serving customers in the bioresearch space through a culture of trust and care.

Diacon Technologies Ltd. is a supplier of anti-sapstain chemicals and delivery systems.

Zelam Limited is a New Plymouth, New Zealand-based company that specializes in the research, development, production, and marketing of crop protection products. Founded in 1988, Zelam offers a range of products including fungicides, herbicides, insecticides, and foliar nutrients, which are marketed locally and internationally. Additionally, the company is involved in the manufacturing and treatment of engineered wood products, and conducts testing in its micro laboratory as well as field trials in New Zealand, Australia, and Hawaii. Zelam's products are marketed under various brand names, including TAG G2, Vixen, Taratek, and Permatek. In April 2006, Zelam Limited changed its name from Taranaki Nuchem Ltd. and is currently a subsidiary of Lonza Group Ltd.

Odyssey Thera, Inc. is a biopharmaceutical company focused on developing therapies for cancer treatment. Founded in 2002 and based in San Ramon, California, the company employs a cellular pharmacology strategy to identify and develop medicines targeting human diseases. Odyssey Thera specializes in deciphering biologically-relevant pathways in living human cells, which enhances drug discovery and improves methods for assessing environmental chemical toxicity. Its product pipeline features small molecule inhibitors designed to block key signaling nodes in cancer cells, reflecting the company's commitment to advancing innovative cancer therapies.

Arch Chemicals, Inc., is a global specialty chemical company based in Norwalk, Connecticut, involved in two main business segments: treatment products and performance products. Treatment products include chemicals to sanitize drinking water and swimming pools; industrial biocides, used to inhibit the growth of microorganisms in metal working fluids, paint, and other coatings; industrial wood preservatives and fire retardants; stains and lacquers to coat wood; and active ingredients and preservatives used in shampoos, cosmetics, and other personal care products. Arch's performance products include polyols used to make adhesives, sealants, and coatings; glycols for making antifreeze, cleaning products, and consumer goods; and hydrazine hydrate, used to make drugs, treat water, and blowing agents that strengthen plastics and rubbers by expanding them. In 2004 Arch sold off most of its microelectronic materials business segment, which provided slurry used by semiconductor manufacturers to remove and polish surfaces. In addition to 16 U.S. locations, Arch maintains operations in 20 other countries around the world. A spinoff of the Olin Corporation in 1999, Arch is a public company listed on the New York Stock Exchange.

Vivante GMP Solutions is a custom manufacturing organization dedicated to producing GMP viral-based therapeutics.

Moda Technology Partners is a commercial software company dedicated to enhancing automation and regulatory compliance in pharmaceutical manufacturing. The company specializes in a mobile data acquisition platform that enables organizations to automate quality control processes for pharmaceuticals and consumer products. By leveraging mobile computing technology, Moda's software systems assist pharmaceutical clients in increasing operational efficiency, improving product quality, and reducing manufacturing costs.

AlgoNomics is a Belgium-based biotech company specializing in structural bioinformatics services aimed at developing rationally designed therapeutics, particularly in the field of immunotherapy. The company possesses a proprietary platform that includes advanced tools for analyzing protein-protein and protein-peptide interactions. Its flagship product, the Epibase platform, focuses on T-cell epitope identification across diverse population groups, facilitating the discovery of vaccines and therapeutic proteins. By providing comprehensive immunogenicity screening services, AlgoNomics supports the development of biotherapeutics designed to enhance immune responses.

Cilian is an emerging biotechnology company developing and marketing a novel expression system. The Company uses a species of Ciliates, a eukaryotic single-cell organism, for the production of enzymes and therapeutic proteins. While Ciliates secrete a number of therapeutically relevant enzymes with high expression rates by nature, recombinant proteins are produced by Ciliates using genetically modified cells. Leveraging the unique capabilities of the Ciliates, the Company aims to produce proteins at an unmatched quality and price, thereby fulfilling its mission to improve human health by facilitating access to biopharmaceuticals.

Amaxa Biosystems GmbH specializes in developing and commercializing gene transfer technologies, notably through its Nucleofector Technology, which facilitates the non-viral transfer of various substrates, including DNA, RNA, and peptides into cells. The company provides a range of products and services, including transfection reagents, antibiotics for combating microbial contamination, and expression vectors for producing fluorescent proteins in mammalian cells. Amaxa's solutions are utilized in primary cell research and are available in multiple countries, including Canada, China, and Japan. Founded in 1998 and headquartered in Cologne, Germany, Amaxa has been a subsidiary of Lonza Group AG since 2008.

SAM Electron Technologies develops an electrochemical cerium-based oxidation technology.

UCB-Bioproducts provides chemical peptide manufacturing services.